Bernard Taverne, Alice Desclaux, Papa Salif Sow

CHAPITRE I-3Evénements indésirables graves comme critère de morbidité et de mortalitéird-00718213, version 1 - 16 Jul 20125. Chou VB, Omer SB, Hussain H, et al. The costs associated withadverse event procedures for an international HIV clinical trialdetermined by activity-based costing. J. Acquir. Immune Defic.Syndr. 2007;46(4):426-432.6. Cook RJ, Lawless JF. Marginal analysis of recurrent events anda terminating event. Stat Med. 1997;16(8):911-924.7. d'Arminio Monforte A, Sabin CA, Phillips A, et al. The changingincidence of AIDS events in patients receiving highly active antiretroviraltherapy. Arch. Intern. Med. 2005;165(4):416-423.8. De Beaudrap P, Etard J, Ecochard R, et al. Change over time ofmortality predictors after HAART initiation in a Senegalese cohort.Eur. J. Epidemiol. 2008;23(3):227-234.9. De Beaudrap P, Etard J, Diouf A, et al. Incidence and determinantsof new AIDS-defining illnesses after HAART initiation in aSenegalese cohort. BMC Infect. Dis. 2010;10:179.10. Deuffic-Burban S, Losina E, Wang B, et al. Estimates of opportunisticinfection incidence or death within specific CD4 strata in HIV-infectedpatients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4count modelling. Eur. J. Epidemiol. 2007;22(10):737-744.11. Duncombe C, Kerr SJ, Ruxrungtham K, et al. HIV diseaseprogression in a patient cohort treated via a clinical researchnetwork in a resource limited setting. AIDS. 2005;19(2):169-178.12. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomesin antiretroviral therapy (ART)-naive participants and in thosenot receiving ART at baseline in the SMART study. J. Infect. Dis.2008;197(8):1133-1144.13. Etard J, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes ofdeath in adults receiving highly active antiretroviral therapy inSenegal: a 7-year cohort study. AIDS. 2006;20(8):1181-1189.14. Guiguet M, Boué F, Cadranel J, et al. Effect of immunodeficiency,HIV viral load, and antiretroviral therapy on the risk ofindividual malignancies (FHDH-ANRS CO4): a prospective cohortstudy. Lancet Oncol. 2009;10(12):1152-1159.15. Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern ofAIDS-defining illnesses with the ntroduction of highly active antiretroviraltherapy (HAART) in a London clinic. J. Infect. 2001;42(2):134-139.16. Iwuji C, Mayanja B, Weiss H, Atuhumuza E, Hughes P, Maher D,Grosskurth H. Morbidity in HIV-1-infected individuals before and afterthe introduction of antiretroviral therapy: a longitudinal study of apopulation-based cohort in Uganda. HIV Med. 2011 Apr 27. 1468-1293.17. Jaén A, Esteve A, Miró JM, et al. Determinants of HIV progressionand assessment of the optimal time to initiate highly activeantiretroviral therapy: PISCIS Cohort (Spain). J. Acquir. ImmuneDefic. Syndr. 2008;47(2):212-220.18. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunisticillnesses occurring after initiation of potent antiretroviral therapy:the Swiss HIV Cohort Study. JAMA. 1999;282(23):2220-2226.19. Marin B, Thiébaut R, Bucher HC, et al. Non-AIDS-definingdeaths and immunodeficiency in the era of combination antiretroviraltherapy. AIDS. 2009;23(13):1743-1753.20. May M, Sterne JAC, Sabin C, et al. Prognosis of HIV-1-infectedpatients up to 5 years after initiation of HAART: collaborativeanalysis of prospective studies. AIDS. 2007;21(9):1185-1197.21. Miller V, Phillips AN, Clotet B, et al. Association of virus load,CD4 cell count, and treatment with clinical progression in humanimmunodeficiency virus-infected patients with very low CD4 cellcounts. J. Infect. Dis. 2002;186(2):189-197.22. Mocroft A, Sabin CA, Youle M, et al. Changes in AIDS-definingillnesses in a London Clinic, 1987-1998. J. Acquir. Immune Defic.Syndr. 1999;21(5):401-407.23. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDSand death rates in the EuroSIDA study: an observational study.Lancet. 2003;362(9377):22-29.24. Mocroft A, Ledergerber B, Zilmer K, et al. Short-term clinicaldisease progression in HIV-1-positive patients taking combinationantiretroviral therapy: the EuroSIDA risk-score. AIDS.2007;21(14):1867-1875.25. Moh R, Danel C, Messou E, et al. Incidence and determinantsof mortality and morbidity following early antiretroviral therapyinitiation in HIV-infected adults in West Africa. AIDS.2007;21(18):2483-2491.26. Moore DM, Hogg RS, Chan K, et al. Disease progression inpatients with virological suppression in response to HAART isassociated with the degree of immunological response. AIDS.2006;20(3):371-377.27. Mugyenyi P, Walker AS, Hakim J, et al. Routine versusclinically driven laboratory monitoring of HIV antiretroviral therapyin Africa (DART): a randomised non-inferiority trial. Lancet.2010;375(9709):123-131.28. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidityand mortality among patients with advanced human immunodeficiencyvirus infection. HIV Outpatient Study Investigators. N.Engl. J. Med. 1998;338(13):853-860.29. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. Grade4 events are as important as AIDS events in the era of HAART. J.Acquir. Immune Defic. Syndr. 2003;34(4):379-386.30. Seyler C, Messou E, Gabillard D, et al. Morbidity before andafter HAART initiation in Sub-Saharan African HIV-infected adults:a recurrent event analysis. AIDS Res. Hum. Retroviruses.2007;23(11):1338-1347.31. Smurzynski M, Wu K, Benson CA, et al. Relationship betweenCD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-definingevents among persons followed in the ACTG longitudinallinked randomized trials study. J. Acquir. Immune Defic. Syndr.2010;55(1):117-127.32. Torti C, Lapadula G, Maggiolo F, et al. Predictors of AIDS-definingevents among advanced naïve patients after HAART. HIV ClinTrials. 2007;8(3):112-120.33. van Sighem AI, van de Wiel MA, Ghani AC, et al. Mortality andprogression to AIDS after starting highly active antiretroviraltherapy. AIDS. 2003;17(15):2227-2236.34. Zhou J, Paton NI, Ditangco R. AIDS-defining illness diagnosedwithin 90 days after starting highly active antiretroviral therapyamong patients from the TREAT Asia HIV ObservationalDatabase. Int J STD AIDS. 2007;18(7):446-452.35. The Antiretroviral Therapy Cohort Collaboration. Causes ofdeath in HIV-1-infected patients treated with antiretroviral therapy,1996-2006: collaborative analysis of 13 HIV cohort studies. Clin.Infect. Dis. 2010;50(10):1387-1396.35